An epidemiological surveillance study to evaluate the incidence of dengue in Brazil
Trial overview
To estimate the incidence of laboratory-confirmed symptomatic dengue infection (all DENV types)
Timeframe: At the end of every year/season
To estimate the incidence of DENV-type specific primary laboratory-confirmed symptomatic dengue infection
Timeframe: Every year/season
To estimate the incidence of DENV-type specific secondary laboratory-confirmed symptomatic dengue infection
Timeframe: Every year/season
To estimate the incidence of primary symptomatic dengue infection (including laboratory-confirmed and probable cases)
Timeframe: Every year/season
To estimate the incidence of secondary symptomatic dengue infection (including laboratory-confirmed and probable cases)
Timeframe: Every year/season
To estimate the prevalence of previous dengue infection(s) (dengue seroprevalence) at baseline
Timeframe: 4 years (Day 0 – Month 48)
To estimate the incidence of primary inapparent dengue infection
Timeframe: Every year/season
To estimate the severity of symptoms of symptomatic dengue (using the 2009 WHO guidelines)
Timeframe: 4 years (Day 0 – Month 48)
- Written, signed or thumb-printed informed consent (and assent when applicable) must be obtained from the subject or subject’s parent(s)/legally acceptable representative(s) (LAR(s)). If the subject/subject’s parent(s)/LAR(s) are illiterate the consent form will be countersigned by a witness.
- Male or female at least 6 months of age at the time of enrollment.
- Child in care.
- Participation (current or planned) in another epidemiological study or in a clinical trial that would conflict with the current study, based on investigator’s judgement.
- Male or female at least 6 months of age at the time of enrollment.
- Subject and/or subject’s parent(s)/LAR(s) who the study staff believes can comply with the requirements of the protocol.
- Subject who plans, at the time of enrollment, to remain at same residence/study area during their study participation period).
Written, signed or thumb-printed informed consent (and assent when applicable) must be obtained from the subject or subject’s parent(s)/legally acceptable representative(s) (LAR(s)). If the subject/subject’s parent(s)/LAR(s) are illiterate the consent form will be countersigned by a witness.
- Participation (current or planned) in another epidemiological study or in a clinical trial that would conflict with the current study, based on investigator’s judgement.
- Terminal illness or severe mental incapacity.
Child in care.
Trial location(s)
Study documents
If you wish to request for full study report, please contact - [email protected]
Results overview
Results posted on ClinicalTrials.gov
Plain language summaries
Plain language summaries of clinical trial results for Phase 2-4 clinical trials that were initiated on or after January 2022 will be posted by GSK within one year following study completion.